Indaptus Therapeutics (NASDAQ: INDP) names David Natan to board

Rhea-AI Filing Summary

Indaptus Therapeutics, Inc. expanded its Board of Directors from eight to nine members and appointed David Natan to fill the new seat. He was named a Class II director with a term running until the 2026 annual meeting of stockholders, when he will stand for election. Natan was designated by David E. Lazar under a securities purchase agreement dated December 22, 2025.

Natan brings extensive finance and public company experience, including leadership roles at multiple companies and service on other public boards and audit committees. He was also appointed to the Audit Committee, replacing Avraham Ben-Tzvi, who will remain on the board and is expected to serve as a paid consultant. The board determined that Natan qualifies as an independent director and meets Nasdaq’s heightened independence standards for audit committee service. He will participate in the company’s non-employee director compensation program.

false 0001857044 0001857044 2026-01-08 2026-01-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

January 8, 2026

Date of Report (Date of earliest event reported)

INDAPTUS THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-40652		86-3158720
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

3 Columbus Circle 15th Floor New York, New York		10019
(Address of principal executive offices)		(Zip Code)

(646) 427-2727

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, $0.01 par value		INDP		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 8, 2026, the Board of Directors (the “Board”) of Indaptus Therapeutics, Inc. (the “Company”) increased its size from eight to nine members and appointed David Natan to fill the vacancy.

David Natan was appointed as a Class II director and will serve a term expiring at the 2026 annual meeting of stockholders, at which point he will stand for election by the shareholders. Mr. Natan is a nominee designated by Mr. David E. Lazar in exercise of Mr. Lazar’s right to recommend three individuals to the Board under a securities purchase agreement dated December 22, 2025.

Mr. Natan currently serves as President and Chief Executive Officer of Natan & Associates, LLC, a consulting firm offering chief financial officer services to public and private companies in a variety of industries, both domestically and internationally, since 2007. From 2010 to May 2020, Mr. Natan served as Chief Executive Officer of ForceField Energy, Inc. (OTCMKTS: FNRG), a company focused on the solar industry and LED lighting products sourced from China. From February 2002 to November 2007, Mr. Natan served as Executive Vice President of Reporting and Chief Financial Officer of Pharma Net Development Group, Inc., a drug development services and clinical trials company, and, from June 1995 to February 2002, as Chief Financial Officer and Vice President of Global Technovations, Inc., a manufacturer and marketer of oil analysis instruments and speakers and speaker components. Prior to that, Mr. Natan served various roles in increasing responsibility with Deloitte & Touche LLP, a global accounting and consulting firm. Mr. Natan currently serves as a member of the Board of Directors and Chair of the Audit Committee of Sunshine Biopharma, Inc. (Nasdaq: SBFM), a pharmaceutical and nutritional supplement company, since February 2022. Additionally, since April 2024, Mr. Natan has served as a member of the Board of Directors and Audit Committee Chair of FIEE, Inc., a technology company specializing in SAAS solutions and Al software development, primarily in Hong Kong. Mr. Natan is a CPA (inactive), holds a B.A. in Economics from Boston University, and was appointed to Omicron Delta Epsilon, an international honor society in the field of Economics. Mr. Natan’s extensive experience as an executive, his background in finance, and his exposure to public companies qualifies him to be on our Board.

Mr. Natan was appointed as a member of the Audit Committee replacing Mr. Avraham Ben-Tzvi whom the Company intends to engage as a paid consultant and who will continue to serve as a director on the Board. In connection with Mr. Natan’s appointment to the Board and the Audit Committee, the Board has determined that Mr. Natan satisfies the definition of “independent director” and the heightened independence standards for service on the Board’s Audit Committee under the NASDAQ listing standards.

Mr. Natan will participate in the Company’s non-employee director compensation plan attached hereto as Exhibit 10.1 and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit Number		Description
10.1+		Indaptus Therapeutics, Inc. Non-Employee Director Compensation Program (Effective April 2, 2023) (incorporated herein by reference to Exhibit 10.1 of the Company’s Quarterly Report on Form 10-Q filed with the SEC on May 11, 2023)
104		Cover Page Interactive Data File

+ Indicates a management contract or compensatory plan or arrangement.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 8, 2026

	INDAPTUS THERAPEUTICS, INC.
	By:	/s/ Nir Sassi
	Name:	Nir Sassi
	Title:	Chief Financial Officer

FAQ

What board change did Indaptus Therapeutics (INDP) disclose?

Indaptus Therapeutics increased its Board of Directors from eight to nine members and appointed David Natan to fill the new board seat.

What is David Natan’s role and term at Indaptus Therapeutics (INDP)?

David Natan was appointed as a Class II director and will serve until the 2026 annual meeting of stockholders, when he will stand for election.

How was David Natan selected for the Indaptus Therapeutics (INDP) board?

He is a nominee designated by David E. Lazar under a securities purchase agreement dated December 22, 2025, which gives Lazar the right to recommend three individuals to the board.

What committee assignments does David Natan have at Indaptus Therapeutics (INDP)?

David Natan was appointed as a member of the Audit Committee, replacing Avraham Ben-Tzvi, who will remain a director and is expected to be engaged as a paid consultant.

Is David Natan considered independent under Nasdaq rules at Indaptus Therapeutics (INDP)?

Yes. The board determined that David Natan meets the definition of an independent director and satisfies the heightened independence standards for audit committee service under Nasdaq listing standards.

How will David Natan be compensated as a director of Indaptus Therapeutics (INDP)?

He will participate in the company’s non-employee director compensation program, which is described in a document incorporated by reference as Exhibit 10.1.